An important question is whether combining MRAs, especially finerenone, with with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) would add a benefit in comparison to the use of each antagonist separately in diabetic kidney disease (DKD) patients on the renal and CV outcomes. Here, SLC5A2 is linked to diabetic kidney disease.